Here, we report a novel STRBP-JAK2 fusion gene in a patient with Ph-like ALL which proved resistant to standard induction chemotherapy and ruxolitinib, but achieved complete remission (CR) after chimeric antigen receptor (CAR) T-cell therapy, allogenic stem cell transplantation (allo-HSCT) and donor lymphocyte infusion (DLI). This evidence concerns the gene STRBP and acute lymphoblastic leukemia.